1. Roth, G. A. et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70, 1-25 (2017).
2. Zhao, D., Liu, J., Wang, M., Zhang, X. & Zhou, M. Epidemiology of cardiovascular disease in china: Current features and implications. Nat. Rev. Cardiol. 16, 203-212 (2019).
3. Noble, N., Paul, C., Turon, H. & Oldmeadow, C. Which modifiable health risk behaviours are related? A systematic review of the clustering of smoking, nutrition, alcohol and physical activity ('snap') health risk factors. Prev. Med. 81, 16-41 (2015).
4. Clarke, G., Stilling, R. M., Kennedy, P. J., Stanton, C., Cryan, J. F. & Dinan, T. G. Minireview: Gut microbiota: The neglected endocrine organ. Mol. Endocrinol. 28, 1221-1238 (2014).
5. David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559-563 (2014).
6. Jie, Z. et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat. Commun. 8, 845 (2017).
7. Brown, J. M. & Hazen, S. L. The gut microbial endocrine organ: Bacterially derived signals driving cardiometabolic diseases. Annu. Rev. Med. 66, 343-359 (2015).
8. Gentile, C. L. & Weir, T. L. The gut microbiota at the intersection of diet and human health. Science 362, 776-780 (2018).
9. Witkowski, M., Weeks, T. L. & Hazen, S. L. Gut microbiota and cardiovascular disease. Circ. Res. 127, 553-570 (2020).
10. Koeth, R. A. et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576-585 (2013).
11. Tilg, H. A gut feeling about thrombosis. New Engl. J. Med. 374, 2494-2496 (2016).
12. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57-63 (2011).
13. Schiattarella, G. G. et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: A systematic review and dose-response meta-analysis. Eur. Heart. J. 38, 2948-2956 (2017).
14. Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. New Eng. J. Med. 368, 1575-1584 (2013).
15. Zhu, Y. et al. Carnitine metabolism to trimethylamine by an unusual rieske-type oxygenase from human microbiota. Proc. Natl. Acad. Sci. U. S. A. 111, 4268-4273 (2014).
16. Zhu, W. et al. Gut microbial metabolite tmao enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111-124 (2016).
17. Zhu, W. F., Wang, Z. N., Tang, W. H. W. & Hazen, S. L. Gut microbe-generated trimethylamine n-oxide from dietary choline is prothrombotic in subjects. Circulation 135, 1671-1673 (2017).
18. Koeth, R. A. et al. L-carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J. Clin. Invest. 129, 373-387 (2019).
19. Koeth, R. A. et al. 𝛾-butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 20, 799-812 (2014).
20. Wu, W. K. et al. Characterization of TMAO productivity from carnitine challenge facilitates personalized nutrition and microbiome signatures discovery. Microbiome 8, 162 (2020).
21. Barabási, A.-L., Menichetti, G. & Loscalzo, J. The unmapped chemical complexity of our diet. Nat. Food 1, 33-37 (2020).
22. Roberts, A. B. et al. Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat. Med. 24, 1407-1417 (2018).
23. Smits, L. P. et al. Effect of vegan fecal microbiota transplantation on carnitine- and choline-derived trimethylamine-N-oxide production and vascular inflammation in patients with metabolic syndrome. J. Am. Heart Assoc. 7, (2018).
24. Wang, Z. et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163, 1585-1595 (2015).
25. Petrovska, B. B. & Cekovska, S. Extracts from the history and medical properties of garlic. Pharmacogn. Rev. 4, 106-110 (2010).
26. Banerjee, S. K. & Maulik, S. K. Effect of garlic on cardiovascular disorders: A review. Nutr. J. 1, 4 (2002).
27. Liperoti, R., Vetrano, D. L., Bernabei, R. & Onder, G. Herbal medications in cardiovascular medicine. J. Am. Coll. Cardiol. 69, 1188-1199 (2017).
28. Rahman, K. & Lowe, G. M. Garlic and cardiovascular disease: A critical review. J. Nutr. 136, 736-740 (2006).
29. Sobenin, I. A., Pryanishnikov, V. V., Kunnova, L. M., Rabinovich, Y. A., Martirosyan, D. M. & Orekhov, A. N. The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. Lipids Health Dis. 9, (2010).
30. Harris, J. C., Cottrell, S. L., Plummer, S. & Lloyd, D. Antimicrobial properties of Allium sativum (garlic). Appl. Microbiol. Biotechnol. 57, 282-286 (2001).
31. Ankri, S. & Mirelman, D. Antimicrobial properties of allicin from garlic. Microbes Infect. 1, 125-129 (1999).
32. Choo, S. et al. Review: Antimicrobial properties of allicin used alone or in combination with other medications. Folia. Microbiol. 65, 451-465 (2020).
33. Reiter, J., Levina, N., van der Linden, M., Gruhlke, M., Martin, C. & Slusarenko, A. J. Diallylthiosulfinate (allicin), a volatile antimicrobial from garlic (Allium sativum), kills human lung pathogenic bacteria, including MDR strains, as a vapor. Molecules 22, (2017).
34. Panyod, S. & Sheen, L. Y. Beneficial effects of chinese herbs in the treatment of fatty liver diseases. J. Tradit. Complement. Med. 10, 260-267 (2020).
35. Panyod, S. et al. Allicin modifies the composition and function of the gut microbiota in alcoholic hepatic steatosis mice. J. Agric. Food. Chem. 68, 3088-3098 (2020).
36. Wu, W. K., Panyod, S., Ho, C. T., Kuo, C. H., Wu, M. S. & Sheen, L. Y. Dietary allicin reduces transformation of L-carnitine to TMAO through impact on gut microbiota. J. Funct. Foods 15, 408-417 (2015).
37. Wu, W.-K. et al. Identification of TMAO-producer phenotype and host–diet–gut dysbiosis by carnitine challenge test in human and germ-free mice. Gut 68, 1439-1449 (2019).
38. Kasahara, K. et al. Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model. Nat Microbiol 3, 1461-1471 (2018).
39. Li, J., Lin, S., Vanhoutte, P. M., Woo, C. W. & Xu, A. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in ApoE-/- mice. Circulation 133, 2434-2446 (2016).
40. Chen, K. et al. Preventive effects and mechanisms of garlic on dyslipidemia and gut microbiome dysbiosis. Nutrients 11, (2019).
41. O'Gara, E. A., Hill, D. J. & Maslin, D. J. Activities of garlic oil, garlic powder, and their diallyl constituents against Helicobacter pylori. Appl. Environ. Microb. 66, 2269-2273 (2000).
42. Naganawa, R., Iwata, N., Ishikawa, K., Fukuda, H., Fujino, T. & Suzuki, A. Inhibition of microbial growth by ajoene, a sulfur-containing compound derived from garlic. Appl. Environ. Microb. 62, 4238-4242 (1996).
43. Casella, S., Leonardi, M., Melai, B., Fratini, F. & Pistelli, L. The role of diallyl sulfides and dipropyl sulfides in the in vitro antimicrobial activity of the essential oil of garlic, Allium sativum L., and leek, Allium porrum L. Phytother. Res. 27, 380-383 (2013).
44. Avato, P., Tursi, F., Vitali, C., Miccolis, V. & Candido, V. Allylsulfide constituents of garlic volatile oil as antimicrobial agents. Phytomedicine 7, 239-243 (2000).
45. Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl Acad. Sci. U. S. A. 110, 9066-9071 (2013).
46. Chelakkot, C. et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp. Mol. Med. 50, (2018).
47. Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of crohn disease patients. Proc. Natl Acad. Sci. U. S. A. 105, 16731-16736 (2008).
48. Panyod, S. et al. Diet supplementation with allicin protects against alcoholic fatty liver disease in mice by improving anti-inflammation and antioxidative functions. J. Agric. Food Chem. 64, 7104-7113 (2016).
49. Beattie, J. H., Duthie, S. J., Kwun, I. S., Ha, T. Y. & Gordon, M. J. Rapid quantification of aortic lesions in ApoE(-/-) mice. J. Vasc. Res. 46, 347-352 (2009).
50. Lai, Y. S. et al. Garlic essential oil protects against obesity-triggered nonalcoholic fatty liver disease through modulation of lipid metabolism and oxidative stress. J. Agric. Food Chem. 62, 5897-5906 (2014).
51. Goodman, A. L. et al. Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. Proc. Natl Acad. Sci. U. S. A. 108, 6252-6257 (2011).
52. Krautkramer, K. A. et al. Diet-microbiota interactions mediate global epigenetic programming in multiple host tissues. Mol. Cell. 64, 982-992 (2016).
53. Mortele, O. et al. Optimization of an in vitro gut microbiome biotransformation platform with chlorogenic acid as model compound: From fecal sample to biotransformation product identification. J. Pharmaceut. Biomed. 175, (2019).
54. Romano, K. A., Vivas, E. I., Amador-Noguez, D. & Rey, F. E. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. mBio 6, e02481 (2015).
55. Wu, W. K. et al. Optimization of fecal sample processing for microbiome study - the journey from bathroom to bench. J. Formos. Med. Assoc. 118, 545-555 (2019).
56. Comeau, A. M., Douglas, G. M. & Langille, M. G. Microbiome helper: A custom and streamlined workflow for microbiome research. mSystems 2, (2017).
57. Rognes, T., Flouri, T., Nichols, B., Quince, C. & Mahe, F. Vsearch: A versatile open source tool for metagenomics. PeerJ 4, e2584 (2016).
58. Caporaso, J. G. et al. Qiime allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335-336 (2010).